State-of-the-art treatment of metastatic hormone-refractory prostate cancer

Susan Goodin, Kamakshi V. Rao, Robert S. DiPaola

    Research output: Contribution to journalReview articlepeer-review

    52 Scopus citations


    Initial therapy for advanced prostate cancer includes androgen ablation by surgical or medical castration. Still, nearly all men with metastases will progress to hormone-refractory prostate cancer (HRPC). Current U.S. Food and Drug Administration-approved agents for the treatment of HRPC include mitoxantrone and estramustine, although the vinca alkaloids and the taxanes have shown promising activity in single-agent phase II trials. Combinations of these agents induce a biochemical response in greater than 50% of patients, but the median duration of response is approximately 6 months. Overall survival of patients treated with these combinations is approximately 18-24 months. Studies are ongoing to develop novel therapies that target specific molecular pathways or mechanisms of chemotherapy resistance. Novel agents under development include growth factor receptor inhibitors, anti-sense oligonucleotides, bisphosphonates, and cell differentiating agents. Evaluation and incorporation of these agents into existing treatment regimens will guide us in the development of more active regimens in the treatment of HRPC.

    Original languageEnglish (US)
    Pages (from-to)360-370
    Number of pages11
    Issue number4
    StatePublished - 2002

    All Science Journal Classification (ASJC) codes

    • General Medicine


    • Hormone-refractory prostate cancer
    • Resistance
    • Taxanes
    • Treatment


    Dive into the research topics of 'State-of-the-art treatment of metastatic hormone-refractory prostate cancer'. Together they form a unique fingerprint.

    Cite this